Amanote Research
Register
Sign In
Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.260
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
H. Yang
C. Qi
J. Zhang
K. El Ouagari
Publisher
Elsevier BV
Related search
Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cytokine Release Syndrome and Neurotoxicity by Baseline Tumor Burden in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma
Current Oncology
Oncology
Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Journal of Health Economics and Outcomes Research
